Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Kymab, Morphosys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Dec 8, 2016

Heptares Scientists Solve Structure of CCR9 Chemokine Receptor offering Unique Opportunity to Apply Structure-Based Design across Chemokine Receptor...

Nov 30, 2016
Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-Focused Drug Discovery and Development

Jan 22-26, 2017
Medicinal & Bioorganic Chemistry Conference
Steamboat, CO, USA
Presenting: Giles Brown

Mar 6-8, 2017
Towards Novel Therapies: Emerging Insights from Structural and Molecular Biology
Groningen, the Netherlands
Presenting: Rob Cooke

© 2012-2017 Heptares Therapeutics